Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Nausea × nabiximols × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 9 Neoplasms 7 Marijuana Abuse 4 Cancer Pain 4 Glioblastoma 2 Squamous Cell Carcinoma of Head and Neck 1 Signs and Symptoms 1 Recurrence 1 Parasomnias 1 Pancreatic Neoplasms 1 Nausea 1 Mouth Neoplasms 1 Marijuana Use 1 Chronic Pain 1 Cachexia 1 Breast Neoplasms 1 Brain Neoplasms 1 Anxiety Disorders 1 Anorexia 1 Advanced Malignant Solid Tumor 1 Advanced Cancer 1 1- Cancer Patients During Chemotherapy Treatment 1

Interventions

Dexamethasone 33 Aprepitant 30 Ondansetron 25 Palonosetron 22 Granisetron 16 Calcium Dobesilate 15 Olanzapine 12 Therapeutics 8 dexamethasone acetate 7 Cyclophosphamide 7 fosaprepitant 6 casopitant 6 Doxorubicin 6 Radiotherapy 5 netupitant 4 dolasetron 4 dexamethasone 21-phosphate 4 Vincristine 4 Tropisetron 4 Metoclopramide 4 Acupressure 4 Prochlorperazine 3 Lorazepam 3 Electroacupuncture 3 Dronabinol 3 Cisplatin 3 peppermint oil 2 netupitant, palosentron drug combination 2 ginger extract 2 auricularum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡